Biotechnology

Pharmaceuticals

Eli Lilly's Ovarian Cancer Breakthrough: FDA Grants Rare Designation to Novel ADC Targeting Treatment-Resistant Disease

Eli Lilly announced FDA Breakthrough Therapy Designation for sofetabart mipitecan (LY4170156), a novel folate receptor alpha-targeted ADC for platinum-resistant ovarian cancer, offering hope to patients with limited treatment options.

Biotechnology

D3 Bio Advances KRAS-Targeted Cancer Pipeline as FDA Clears Two Critical Clinical Programs

In a significant regulatory milestone that underscores the growing momentum in precision oncology, Shanghai-based D3 Bio announced today that the U.S. Food and Drug Administration has cleared two Investigational New Drug (IND) applications, enabling the company to advance its next-generation KRAS-targeted therapies into critical clinical trials.

Biotechnology

Antengene's Next-Generation Cancer Arsenal Shows Promise as ADC Platform Delivers Strong Clinical Results

Antengene Corporation presented compelling clinical data at the J.P. Morgan Healthcare Conference, showcasing robust efficacy results for its lead antibody-drug conjugate (ADC) and unveiling an ambitious pipeline of next-generation cancer treatments.

Pharmaceuticals

Novartis Achieves Historic Milestone: Ianalumab Becomes First Targeted Therapy to Earn FDA Breakthrough Status for Sjögren's Disease

Novartis announces FDA Breakthrough Therapy Designation for ianalumab in Sjögren's disease, marking the first targeted therapy to receive this recognition for the autoimmune condition.

Biotechnology

Ipsen's Revolutionary Cancer Immunotherapy Earns FDA Breakthrough Status in Blood Cancer Fight

In a significant advancement for cancer immunotherapy, French pharmaceutical company Ipsen announced on January 13, 2026, that the FDA has granted Breakthrough Therapy Designation to IPN60340 (ICT01), a first-in-class monoclonal antibody targeting acute myeloid leukemia (AML). This regulatory milestone positions the therapy as a potentially transformative treatment for

Pharmaceuticals

Historic FDA Approval: Zycubo Becomes First Treatment for Menkes Disease, Delivering 10-Fold Survival Improvement

Sentynl Therapeutics receives FDA approval for Zycubo, the first and only treatment for Menkes disease, offering a 10-fold improvement in survival for children with this devastating rare genetic disorder.

Biotechnology

Chinese Biotech Abbisko Challenges Established Players in Rare Tumor Market as FDA Accepts Pimicotinib Application

Abbisko Therapeutics' FDA acceptance of pimicotinib NDA marks a significant regulatory milestone in the competitive TGCT market, challenging established players like Deciphera and Daiichi Sankyo.

Biotechnology

Beyond Weight Loss: French Biotech Pioneers First-in-Class GLP-1 Therapy for Joint Disease as Osteoarthritis Market Awaits Its First Disease-Modifying Drug

French biotech 4Moving Biotech achieves FDA IND clearance for 4P004, a first-in-class intra-articular GLP-1 therapy targeting osteoarthritis, potentially becoming the first disease-modifying osteoarthritis drug (DMOAD) to reach patients.

Biotechnology

Oculis Achieves Historic Breakthrough: FDA Grants First-Ever Neuroprotective Therapy Designation for Optic Neuritis

In a landmark achievement that could transform treatment for one of neuro-ophthalmology's most challenging conditions, Oculis Holding AG announced on January 6, 2026, that the FDA has granted Breakthrough Therapy Designation to Privosegtor for the treatment of optic neuritis. This designation marks the first time any investigational

Biotechnology

Revolution Medicines Achieves Historic First: FDA Grants Breakthrough Therapy Designation for KRAS G12D-Targeted Cancer Drug

Revolution Medicines announces FDA Breakthrough Therapy Designation for zoldonrasib, marking the first investigational drug specifically targeting the KRAS G12D mutation to receive this prestigious regulatory recognition.

Biotechnology

Krystal Biotech's Gene Therapy Breakthrough: KB407 Shows Promise in Addressing Cystic Fibrosis at Its Genetic Root

Krystal Biotech announces interim clinical results from its Phase 1 CORAL-1 study of KB407, a potentially mutation-agnostic gene therapy for cystic fibrosis that could transform treatment for all CF patients.

Biotechnology

Jazz Pharmaceuticals' Ziihera Achieves Unprecedented Survival in Gastric Cancer: Over Two Years Median Overall Survival Marks New Treatment Paradigm

Jazz Pharmaceuticals announces unprecedented survival outcomes for Ziihera in HER2-positive gastroesophageal adenocarcinoma, achieving over two years median overall survival—the longest ever reported in a Phase 3 trial for this disease.